CN1415301A - Compound recipe formula containing kurarinone prostaglandin E1 and aspirin, its preparation method and application - Google Patents
Compound recipe formula containing kurarinone prostaglandin E1 and aspirin, its preparation method and application Download PDFInfo
- Publication number
- CN1415301A CN1415301A CN 02146488 CN02146488A CN1415301A CN 1415301 A CN1415301 A CN 1415301A CN 02146488 CN02146488 CN 02146488 CN 02146488 A CN02146488 A CN 02146488A CN 1415301 A CN1415301 A CN 1415301A
- Authority
- CN
- China
- Prior art keywords
- prostaglandin
- kurarinone
- aspirin
- preparation
- compound preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960001138 acetylsalicylic acid Drugs 0.000 title claims abstract description 28
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 150000001875 compounds Chemical class 0.000 title claims abstract description 18
- LTTQKYMNTNISSZ-MWTRTKDXSA-N (2S)-(-)-kurarinone Chemical compound C1([C@H]2OC=3C(C[C@@H](CC=C(C)C)C(C)=C)=C(O)C=C(C=3C(=O)C2)OC)=CC=C(O)C=C1O LTTQKYMNTNISSZ-MWTRTKDXSA-N 0.000 title claims description 33
- XQVFLLMCNGKXSM-UHFFFAOYSA-N kurarinone Natural products COc1cc(O)c(C(CC=C(C)C)C(=C)C)c2OC(CC(=O)c12)c3ccc(O)cc3O XQVFLLMCNGKXSM-UHFFFAOYSA-N 0.000 title claims description 33
- KDADHLPROOOPIC-UHFFFAOYSA-N neokurarinol Natural products COc1cc(O)ccc1C1CC(=O)c2c(OC)cc(O)c(CC(CCC(C)(C)O)C(C)=C)c2O1 KDADHLPROOOPIC-UHFFFAOYSA-N 0.000 title claims description 33
- 238000002360 preparation method Methods 0.000 title claims description 26
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 title abstract description 3
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 title abstract 2
- 229960000711 alprostadil Drugs 0.000 title abstract 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 title abstract 2
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 16
- 239000001116 FEMA 4028 Substances 0.000 claims abstract description 16
- 229960004853 betadex Drugs 0.000 claims abstract description 16
- 208000006454 hepatitis Diseases 0.000 claims abstract description 9
- 231100000283 hepatitis Toxicity 0.000 claims abstract description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 6
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 6
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 6
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 6
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 37
- 239000008227 sterile water for injection Substances 0.000 claims description 11
- 229940119744 dextran 40 Drugs 0.000 claims description 6
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 6
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 229930015582 oxymatrine Natural products 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 3
- 239000002158 endotoxin Substances 0.000 claims description 3
- 239000013067 intermediate product Substances 0.000 claims description 3
- 238000005374 membrane filtration Methods 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 10
- 238000002347 injection Methods 0.000 abstract description 4
- 239000007924 injection Substances 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 2
- 238000002156 mixing Methods 0.000 abstract description 2
- 239000000843 powder Substances 0.000 abstract description 2
- XMUPAAIHKAIUSU-QRQCRPRQSA-N kurarinol Chemical compound C1([C@H]2OC=3C(C[C@@H](CCC(C)(C)O)C(C)=C)=C(O)C=C(C=3C(=O)C2)OC)=CC=C(O)C=C1O XMUPAAIHKAIUSU-QRQCRPRQSA-N 0.000 abstract 4
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000012047 saturated solution Substances 0.000 description 8
- 230000001093 anti-cancer Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 2
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229930014456 matrine Natural products 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- -1 aspirin compound Chemical class 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A compound medicine containing kurarinol, prostaglandic E1 and aspirin is prepared through including the kurarinol and prostaglandin E1 by 6-0-malto-beta-cyclodextrin, mixing, adding others, and preparing the freeze dried powder injection. It can be used for treating cancers, cardiovascular and cerebrovascular diseases and hepatitis. Its advantages are sure curative effect, and no toxic by-effect.
Description
Technical field:
The present invention relates to a kind of medicine and its production and use, particularly a kind of kurarinone, prostaglandin E of containing
1With compound preparation of aspirin and its production and use.
Background technology:
Known kurarinone is extraction from Chinese crude drug Radix Sophorae Flavescentis or Radix Sophorae Tonkinensis, purification, the refining and monomer effective ingredient that obtains.Effects such as that pharmacology and clinical trial certificate, kurarinone have is anticancer, leukocyte increasing, anti-hepatitis virus, protection hepatocyte, but its anticancer mechanism only is an anticancer, and also the effect of this inhibition is significantly only not close with cyclophosphamide.Simultaneously, patient's feels pain when the Matrine Injection that uses uses at present is difficult to accept.
Known, prostaglandin E
1Has anticancer, promote the effect that cancerous cell transforms to normal cell, have simultaneously regulate human immune system, blood vessel dilating, inhibition platelet aggregation and, improve the function of microcirculation in human body, have radiation-resistant function simultaneously, regulate immunity, blood circulation promoting and blood stasis dispelling and prevent that the damage that radiotherapy brings has positive clinical effect for cancer patient.
Because prostaglandin E
1Also have expansion liver blood vessel function, can improve the hepatitis liver microcirculation, remove immune complex in liver and the blood, suppress the hepatic necrosis factor and discharge, the protection hepatocyte, and can promote hepatic cell growth, can be used for treating first, second, hepatitis C.It is still good cardiovascular and cerebrovascular disease medication simultaneously, is the wide spectrum endogenous substance of new generation of generally acknowledging, but has the directly side effect of anti-hepatitis virus and injection pain, makes application be restricted.
Known aspirin is good analgesic medicine, but can suppress PGI in the human body
2Synthetic, life-time service or consumption conference aggravation cardiovascular and cerebrovascular disease slightly take place or the aggravation disease.
Summary of the invention:
The objective of the invention is to utilize the mechanism of curing the disease of said medicine, a kind of have kurarinone, prostaglandin E are provided
1With the aspirin compound preparation, by the synergism of medicine, improve curative effect, and alleviate side effect human body.
Another object of the present invention provides the preparation method of this compound preparation.
A further object of the present invention is that the compound preparation that will provide is used for the treatment of cancer, cardiovascular and cerebrovascular disease and hepatitis.
Above-mentioned purpose of the present invention can realize by following technological means.
The component of this compound preparation is as follows:
The composition weight proportioning
Kurarinone 0.5-1.0g
Prostaglandin E
1100-400 μ g
2-6 times of prostaglandin E of 6-0-malt sugar group-beta-cyclodextrin
1Molal quantity
Aspirin or aspisol 0.25-0.9g
Sterilized water for injection or normal saline 0.6-2.2g
Low molecular dextran-40 2-10%
The preparation method of this compound preparation is as follows:
The kurarinone feed purification becomes to contain oxymatrine 99-102%; Prostaglandin E
1Being refined into purity is 99.5%, matrine and prostaglandin E
1Comprise with the 6-0-malt sugar group-beta-cyclodextrin respectively, aspirin or aspisol are dissolved in sterile water for injection or normal saline, the low molecular dextran-40 that is incorporated as gross weight 2-10% is as excipient, the adjustment pH value is 6.0-7.0, after using 0.22 μ m membrane filtration to remove antibacterial, measuring bacterial endotoxin, clarity, pH value, each constituent content of intermediate products carries out fill, false add plug after all qualified, carries out lyophilization in-45-30 ℃ under the vacuum of 2-15Pa, make water content≤2-3%, tamponade, roll lid, after the assay was approved encapsulation.
The present invention has following advantage:
1. prescription is novel unique, and each component is replenished mutually, makes therapeutic effect definite, treats widely, nontoxic, and side effect is slight.
(1) kurarinone has the anticancer function, but effect is not remarkable, prostaglandin E
1Use with kurarinone is collaborative, can significantly improve the function of anticancer, can break up cancerous cell simultaneously and transform prostaglandin E to normal cell
1Adjusting human immune system effect and blood circulation promoting and blood stasis dispelling and prevent that the damage that radiotherapy brings has positive clinical effect, the function of promoting blood circulation to disperse blood clots of aspirin is favourable to cancer patient treatment and rehabilitation, especially its good analgesic effect;
(2) prostaglandin E
1With aspirin or aspisol coupling, can remedy aspirin or aspisol to the synthetic PGI of human body
2The side effect that suppresses, prostaglandin E
1Can strengthen the human body complex functionality, itself also have and PGI simultaneously
2Identical physiological effect, thus overcome the untoward reaction of aspirin or aspisol to human body;
(3) analgesic activity of aspirin or aspisol can reduce kurarinone and prostaglandin E
1Injection pain;
(4) prostaglandin E
1With kurarinone Synergistic treatment hepatitis, can enlarge kurarinone and only treat hepatitis B and can treat first, second, the third three type hepatitis to this compound preparation.
2. the lyophilized injectable powder that compound preparation of the present invention is made makes medicine under aseptic apyrogeneity state, has both guaranteed that patient did not produce hazards of medication, also guarantee medicine produce and use in physicochemical property and physiological action do not change.
3. in the production technology of the present invention, adopt the 6-0-malt sugar group-beta-cyclodextrin to comprise kurarinone and prostaglandin E respectively first
1Both are carried out insulation blocking, guarantee not react between them or respond, thereby guarantee both effectiveness, reduce side effect with aspirin (or aspisol).
4. compound preparation of the present invention is of many uses, can treat cancer, cardiovascular and cerebrovascular disease and hepatitis.
The specific embodiment:
In conjunction with the embodiments the present invention is further detailed now.
The following example does not limit protection scope of the present invention.
Embodiment 1:
Prescription:
It is 99.5% prostaglandin E that the composition weight proportioning contains oxymatrine 99-102% kurarinone 500-700g purity
12-2.5 times of prostaglandin E of 100-250mg 6-0-malt sugar group-beta-cyclodextrin
1Molal quantity purity is 98% aspirin 250-300g
Purity is 98% or aspisol 450-550g
Sterilized water for injection 1500ml
Low molecular dextran-40 2-10%
Kurarinone is dissolved into makes saturated solution in the sterilized water for injection, the 6-0-malt sugar group-beta-cyclodextrin is dissolved into makes saturated solution in the sterilized water for injection, under agitation the kurarinone saturated solution is added drop-wise in the 6-0-malt sugar group-beta-cyclodextrin saturated solution, up to dissolving fully.
With prostaglandin E
1Become saturated solution with anhydrous alcohol solution, the 6-0-malt sugar group-beta-cyclodextrin is dissolved into makes saturated solution in the sterilized water for injection, under agitation with prostaglandin E
1The dehydrated alcohol saturated solution be added drop-wise in the 6-0-malt sugar group-beta-cyclodextrin saturated solution, up to fully the dissolving.
With kurarinone/6-0-malt sugar group-beta-cyclodextrin mixed solution and prostaglandin E
1/ 6-0-malt sugar group-beta-cyclodextrin mixed solution mixing and stirring, add a certain amount of sterilized water for injection again, make overall solution volume reach 1500ml, add aspirin or aspisol, stirring is dissolved it fully, adjust pH value to 6.0-7.0, remove antibacterial and remove undissolved particle through 0.22 μ m membrane filtration, measure the bacterial endotoxin of intermediate products, clarity, pH value, after each constituent content is all qualified, with 1000 of 3ml cillin bottle packing, every 1.5ml fill amount, under the vacuum of 2-15Pa, carry out lyophilization in-45-30 ℃, make water content≤2-3%, the moulding plug, roll aluminium-plastic cap, after the assay was approved encapsulation.
Embodiment 2:
Prescription: composition weight proportioning
Contain oxymatrine 99-102% kurarinone 800-1000g
Purity is 99.5% prostaglandin E
1300-400mg
5.5-6 times of prostaglandin E of 6-0-malt sugar group-beta-cyclodextrin
1Molal quantity
Purity is 98% aspirin 400-500g
Purity is 98% or aspisol 800-900g
Sterilized water for injection 1500ml
Low molecular dextran-40 2-10%
Concrete preparation method is identical with embodiment 1.
Claims (8)
1. one kind contains kurarinone, prostaglandin E
1Compound preparation with aspirin is characterized in that, the prescription below adopting:
The composition weight proportioning
Kurarinone 0.5-1.0g
Prostaglandin E
1100-400 μ g
2-6 times of prostaglandin E of 6-0-malt sugar group-beta-cyclodextrin
1Molal quantity
Aspirin or aspisol 0.25-0.9g
Sterilized water for injection or normal saline 0.6-2.2g
Low molecular dextran-40 2-10%
2. a kind of kurarinone, prostaglandin E of containing according to claim 1
1With the compound preparation of aspirin, oxymatrine concentration is 99-102% in the kurarinone during its feature also is to fill a prescription, and the weight proportion of kurarinone is 0.6-0.8g.
3. a kind of kurarinone, prostaglandin E of containing according to claim 1
1With the compound preparation of aspirin, its feature also is: the prostaglandin E in the prescription
1Purity is 99.5%, and weight proportion is 100-200 μ g.
4. one kind contains kurarinone, prostaglandin E
1Preparation method with the compound preparation of aspirin is characterized in that:
(1) adopt following prescription:
The composition weight proportioning
Kurarinone 0.5-1.0g
Prostaglandin E
1100-400 μ g
2-6 times of prostaglandin E of 6-0-malt sugar group-beta-cyclodextrin
1Molal quantity
Aspirin or aspisol 0.25-0.9g
Sterilized water for injection or normal saline 0.6-2.2g
Low molecular dextran-40 2-10%
(2) adopt following steps:
A. the kurarinone feed purification becomes to contain oxymatrine 99-102%, comprises with the 6-0-malt sugar group-beta-cyclodextrin;
B. prostaglandin E
1Being refined into purity is 99.5%, comprises with the 6-0-malt sugar group-beta-cyclodextrin;
C. to kurarinone and prostaglandin E
1Mixed solution in add sterile water for injection or normal saline, add aspirin or aspisol again, adjust pH value, after using 0.22 μ m membrane filtration to remove antibacterial, carry out fill, false add plug, tamponade after the lyophilization after bacterial endotoxin, clarity, pH value, each constituent content of mensuration intermediate products is all qualified, roll lid, after the assay was approved packing.
5. a kind of kurarinone, prostaglandin E of containing according to claim 4
1With the preparation method of the compound preparation of aspirin, its feature also is: the pH value among the step c is 6.0-7.0.
6. a kind of kurarinone, prostaglandin E of containing according to claim 4
1With the preparation method of the compound preparation of aspirin, its feature also is: the lyophilization among the step c is under the vacuum of 2-15Pa, carries out in-45-30 ℃, makes water content≤2-3%.
7. a kind of kurarinone, prostaglandin E of containing according to claim 4
1With the preparation method of the compound preparation of aspirin, its feature also is: adopt the fill of 3ml cillin bottle among the step c, supporting plug and aluminium-plastic cap.
8. one kind contains kurarinone, prostaglandin E
1Purposes with the compound preparation of aspirin is characterized in that: be used for the treatment of cancer, cardiovascular and cerebrovascular disease and hepatitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02146488 CN1415301A (en) | 2002-11-12 | 2002-11-12 | Compound recipe formula containing kurarinone prostaglandin E1 and aspirin, its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02146488 CN1415301A (en) | 2002-11-12 | 2002-11-12 | Compound recipe formula containing kurarinone prostaglandin E1 and aspirin, its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1415301A true CN1415301A (en) | 2003-05-07 |
Family
ID=4751088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02146488 Pending CN1415301A (en) | 2002-11-12 | 2002-11-12 | Compound recipe formula containing kurarinone prostaglandin E1 and aspirin, its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1415301A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005091937A3 (en) * | 2004-03-04 | 2006-03-30 | Univ California | Compositions useful for the treatment of microbial infections |
| CN101019872B (en) * | 2007-03-08 | 2010-12-01 | 蔡海德 | Nanometer antiviral liposome medicine and its preparation |
| US7846895B2 (en) | 2006-09-06 | 2010-12-07 | The Regents Of The University Of California | Selectively targeted antimicrobial peptides and the use thereof |
| CN102335179A (en) * | 2011-06-03 | 2012-02-01 | 蔡海德 | Alprostadil composite medicine, preparation method thereof, quality controlling method thereof, and purpose thereof |
| CN103816529A (en) * | 2014-03-20 | 2014-05-28 | 蔡欣 | Pharmaceutical composition for treating various serious diseases and preparation and use thereof |
-
2002
- 2002-11-12 CN CN 02146488 patent/CN1415301A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005091937A3 (en) * | 2004-03-04 | 2006-03-30 | Univ California | Compositions useful for the treatment of microbial infections |
| US7875598B2 (en) | 2004-03-04 | 2011-01-25 | The Regents Of The University Of California | Compositions useful for the treatment of microbial infections |
| US7846895B2 (en) | 2006-09-06 | 2010-12-07 | The Regents Of The University Of California | Selectively targeted antimicrobial peptides and the use thereof |
| US8680058B2 (en) | 2006-09-06 | 2014-03-25 | The Regents Of The University Of California | Selectively targeted antimicrobial peptides and the use thereof |
| US9351490B2 (en) | 2006-09-06 | 2016-05-31 | The Regents Of The University Of California | Selectively targeted antimicrobial peptides and the use thereof |
| US10111926B2 (en) | 2006-09-06 | 2018-10-30 | The Regents Of The University Of California | Selectively targeted antimicrobial peptides and the use thereof |
| CN101019872B (en) * | 2007-03-08 | 2010-12-01 | 蔡海德 | Nanometer antiviral liposome medicine and its preparation |
| CN102335179A (en) * | 2011-06-03 | 2012-02-01 | 蔡海德 | Alprostadil composite medicine, preparation method thereof, quality controlling method thereof, and purpose thereof |
| CN103816529A (en) * | 2014-03-20 | 2014-05-28 | 蔡欣 | Pharmaceutical composition for treating various serious diseases and preparation and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101683359B (en) | A kind of traditional Chinese medicine composition for treating tumor and preparation method thereof | |
| CN1415301A (en) | Compound recipe formula containing kurarinone prostaglandin E1 and aspirin, its preparation method and application | |
| CN1169561C (en) | Medicine for treating diseases of rectum and anus | |
| CN102406665A (en) | Application of physically modified cobra venom in preparing medicine for treating arthritis | |
| CN1541699A (en) | Freeze-dried qi-strengthening ginseng and astragalus powder for injection and its preparing process | |
| CN1217669C (en) | Naringin used in preparing medicine for curing acute and chronic bronchitis | |
| CN1105570C (en) | Medicinal composition for curing arthritis and osteoarthropathy and its preparing method | |
| CN1522746A (en) | Rhodiola root medicinal preparation and preparation method and application thereof | |
| CN1426783A (en) | Application of evodiamine in the preparation of medicine | |
| CN1803811A (en) | Nitro imidazole derivative, its preparation method and uses | |
| CN1059831C (en) | Chinese medicinal preparation for treating leukemia | |
| CN1193790C (en) | Thymosin composition injection and its prepn | |
| CN1212130C (en) | Medicine for treating psoriasis, ichthyosis and eczema | |
| CN101185629A (en) | Decitabine sustained-release preparation for treating solid tumor | |
| CN1219539C (en) | Immune regulator prepared from waste material in preparing Mailuoning injection process and its use in producing medicine | |
| CN1233313C (en) | Gel agent for treating acne and its preparation method | |
| CN1698803A (en) | Compound notoginseng injection and its preparation process | |
| CN1204891C (en) | A kind of injection containing tramadol and application thereof | |
| CN1359678A (en) | Process for preparing houttuyninum sodium injection | |
| CN1424028A (en) | Medicine for treating cancers and use thereof | |
| CN1850149A (en) | Compounded preparation of Radix As tragali seu Hedy ari extract and mushroom polysaccharide and preparing method | |
| CN1730014A (en) | Novel drug administration route of semen armeniacae amarum injection, its preparation process and new indications | |
| CN1246004C (en) | Compound shark chondroitin | |
| CN1312091A (en) | Vaginitis treating medicine | |
| CN1768762A (en) | Novel drug administering route of pantocrine injection, its preparation process and novel indications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |